Description: Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that has completed phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Home Page: www.activebiotech.com
ScheelevAegen 22
Lund,
223 63
Sweden
Phone:
46 46 19 20 00
Officers
| Name | Title |
|---|---|
| Ms. Helen Tuvesson Ph.D. | President & CEO |
| Mr. Hans Kolam | Chief Financial Officer |
| Dr. Erik Vahtola | Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.6215 |
| Price-to-Sales TTM: | 21.6719 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |